Anti-Inflammatory Biologics Market Size to reach USD 149.80 Billion

The global anti-inflammatory biologics market size is expected to reach USD 149.80 billion by 2027, exhibiting a CAGR of 11.0% during the forecast period. The indication of an inflammatory surplus in patients with COVID-19 along with plentiful neutrophils and macrophages will revivify growth prospects for the anti-inflammatory biologics market share during the forecast period. The ongoing trials for anti-tumor necrosis factor (TNF) antibodies in severe cases of autoimmune inflammatory disease such as rheumatoid arthritis, inflammatory bowel disease, or ankylosing spondylitis will aid the speedy expansion of the market during the forecast period, mentioned by Fortune Business Insights, in a report, titled “Anti-Inflammatory Biologics Market Size, Share & Industry Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection (Subcutaneous and Intravenous)), By Distribution Channel (Hospital Pharmacy Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027” the market size stood at USD 64.84 billion in 2019. Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/anti-inflammatory-biologics-market-102733 Diseases to Foster Growth The rising cases of autoimmune inflammatory diseases such as psoriasis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, ulcerative colitis, and others is a key factor driving the anti-inflammatory biologics market. According to the National Psoriasis Foundation, in 2017, 125 million people across the world were estimated to have psoriasis. As per the World Health Organization, Osteoarthritis is one of the ten most disabling diseases in developed countries, which affects 9.6% of men and 18.0% of women aged over 60 years worldwide. Moreover, the World Health Organization also states 80% of those with osteoarthritis will have limitations in movement, and 25% cannot perform their major daily activities of life. Besides, the rapid adoption of biologics for the treatment of inflammatory diseases will support the market trajectory in the foreseeable future.